Pharma & Biotech Events & Conferences
Refine Search
Biotechnology
Cellular immunotherapy specialist Fate Therapeutics soared as much as 73%, and closed up 12.45 at $2.27 yesterday, after it released early-stage data on its FT819 in lupus. 19 November 2024
Pharmaceutical
US clinical-stage biopharmaceutical company Boston Pharmaceuticals has announced positive results from a Phase II study evaluating the safety and efficacy of once-monthly efimosfermin alfa (formerly known as BOS-580), a long-acting FGF21 analogue, in participants with stage F2/F3 fibrosis due to metabolic dysfunction-associated steatohepatitis (MASH). 18 November 2024
Pharmaceutical
French drugmaker Ipsen today announced the long-term efficacy and safety of patients treated with Bylvay (odevixibat) from two Phase III open-label extension studies. 18 November 2024
Pharmaceutical
US antiviral giant Gilead Sciences on Friday unveiled two-and-a-half-year interim analysis from the ongoing Phase III ASSURE study of its Livdelzi (seladelpar). 16 November 2024
Pharmaceutical
French drugmaker Ipsen announced late-breaking data for Iqirvo (elafibranor 80mg tablets) from an interim analysis of the ongoing open-label extension of the Phase III ELATIVE study at the American Association for the Study of Liver Disease (AASLD) congress. 16 November 2024
Biotechnology
Belgian drugmaker UCB and US biotech Biogen’s Phase III PHOENYCS GO trial results signal a pivotal development for systemic lupus erythematosus (SLE) treatment, as dapirolizumab pegol met its primary endpoint and demonstrated enhanced disease control and safety at Week 48. 13 November 2024
Biotechnology
Syndax Pharmaceuticals has announced that its Phase II AUGMENT-101 trial of experimental drug revumenib achieved its primary endpoint. 13 November 2024
Pharmaceutical
Research results featured heavily in the news last week, first with Viking Therapeutics releasing promising early-stage data for its investigational medicine VK2738 at the ObesityWeek meeting. US biotech Beam Therapeutics released early-stage data on its sickle cell disease candidate BEAM-101. Also of note, Arcus Biosciences and Gilead Sciences announced promising Phase III results for their TIGIT inhibitor domvanalimab in combination with zimberelimab. Denmark’s Novo Nordisk released financial results that attracted interest. 10 November 2024
Biotechnology
Shanghai-based BioCity Biopharma has announced promising late-stage results from the Phase II 2-SUCCEED clinical trial of SC0062. 7 November 2024
Biotechnology
Results from the ARC-10 Phase III study of Arcus Biosciences and Gilead Sciences’ domvanalimab and zimberelimab combination therapy indicate a significant reduction in mortality risk for patients with certain advanced lung cancers. 7 November 2024
Biotechnology
Beam Therapeutics will detail new clinical and preclinical data on its sickle cell disease (SCD) therapies at the upcoming American Society of Hematology (ASH) meeting. 6 November 2024
Pharmaceutical
AstraZeneca has presented early results on three experimental weight-loss drugs at the ObesityWeek conference in San Antonio, showing encouraging signs for its obesity pipeline. 5 November 2024
Pharmaceutical
US neuroscience-focused biopharma Neurocrine Biosciences presented new data from more than 300 patients diagnosed with tardive dyskinesia and treated with Ingrezza (valbenazine) capsules at the 2024 Psych Congress in Boston. 5 November 2024
Pharmaceutical
Viking Therapeutics (Nasdaq: VKTX) reported promising early results for its experimental obesity pill, VK2735, with increased weight loss at higher doses. 4 November 2024
Pharmaceutical
The US subsidiary of Israel’s Teva Pharmaceutical Industries has announced new, positive data on social functioning and quality of life from the Phase III subcutaneous olanzapine extended-release injection study (SOLARIS) trial evaluating TEV-'749 in adult patients diagnosed with schizophrenia. 2 November 2024
Biotechnology
UCB has reported Phase IIa data from the TOGETHER (AH0003) study, investigating the safety, efficacy, and tolerability of bepranemab - an investigational anti-tau antibody targeting the mid-region of the tau protein - in people living with prodromal to mild Alzheimer’s disease. 1 November 2024
Biosimilars
The US unit of South Korea-based biosimilar drug developer Celltrion
has announced a late-breaking post hoc analysis of the pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC) of Zymfentra (infliximab-dyyb), during the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting. 30 October 2024
Biotechnology
US pharma major Eli Lilly has released results from two, multi-year, Phase III studies that showed patients treated with mirikizumab sustained stable, long-term remission across two types of inflammatory bowel diseases (IBD), ulcerative colitis (UC) and Crohn’s disease. 28 October 2024
Biotechnology
California’s Vera Therapeutics has released 96-week follow-up results from its ORIGIN Phase IIb trial of atacicept, targeting IgA nephropathy (IgAN). 28 October 2024
Biotechnology
After a few disappointments in earlier clinical stages, a new post-hoc analysis of pooled data from the TULIP Phase III clinical trials being presented at the annual European Congress of Rheumatology (EULAR 2021) showed anifrolumab was consistently associated with improvements in both skin rash and arthritis across three different disease measures each, compared to placebo, in patients with moderate to severe systemic lupus erythematosus (SLE). 2 June 2021
Pharmaceutical
The annual meeting of the American Society of Clinical Oncology (ASCO) kicks off online on June 4, with more than 2,500 abstract presentations representing cutting-edge research from around the world. 28 May 2021
Biotechnology
US pharma major Merck & Co’s presentations at this year’s ASCO annual meeting will focus primarily on three products. 25 May 2021
Biotechnology
This year’s annual meeting of the American Society of Clinical Oncology (ASCO) is a chance for Shanghai’s Junshi Biosciences to shine. 25 May 2021
Pharmaceutical
While UK-based drugmaker AstraZeneca has mostly made headlines of late for its development of a coronavirus vaccine, the firm’s work in oncology is potentially of greater significance. 25 May 2021
Biotechnology
Swiss pharma giant Novartis will present new data from its portfolio of approved and investigational targeted, radioligand, cell and gene and immunotherapies at the upcoming 2021 ASCO Annual Meeting. 25 May 2021
Biotechnology
At this year’s ASCO meeting, Bristol Myers Squibb will present the first data from a Phase III trial evaluating a LAG-3-blocking antibody. 20 May 2021
Biotechnology
Sanofi has presented detailed results from the Phase III VOYAGE trial, showing that Dupixent (dupilumab) significantly reduced severe asthma attacks, and within two weeks rapidly improved lung function in children aged 6 to 11 years. 17 May 2021
Pharmaceutical
At the annual meeting of the American College of Cardiology (ACC), poor results for Novartis’ Entresto (sacubitril/valsartan) have disappointed. 17 May 2021
Pharmaceutical
Detailed results from the Phase III DARE-19 trial, testing AstraZeneca's (LSE: AZN) SGLT2 blocker Farxiga (dapagliflozin) in COVID-19, show no significant benefit for patients. 17 May 2021
Pharmaceutical
Bristol Myers Squibb has announced a new analysis of data from the Phase III EXPLORER-HCM study of mavacamten, the firm’s investigational, first-in-class cardiac myosin inhibitor. 17 May 2021
Biotechnology
Shares of oncology focussed US biotech firm Curis closed up 65.5% at $16.27 yesterday, after it announced that two abstracts for CA-4948, a novel, small molecule IRAK4 inhibitor, have been accepted for oral and poster presentation at the European Hematology Association 2021 Virtual Congress (EHA), which will be held virtually June 9-17, 2021. 13 May 2021
Biotechnology
US biotech Regeneron Pharmaceuticals and French partner Sanofi have announced positive results from the Phase III trial of their PD-1 inhibitor Libtayo (cemiplimab) in patients with recurrent or metastatic cervical cancer who had previously progressed on chemotherapy. 13 May 2021
Biotechnology
Horizon Therapeutics has announced new data on Uplinza (inebilizumab-cdon) were presented at the American Academy of Neurology’s 73rd Annual Meeting being held virtually April 17-22, 2021 (AAN 2021). 23 April 2021
Pharmaceutical
Ireland-headquartered Jazz Pharmaceuticals has announced positive results from a Phase III study of Xywav (calcium, magnesium, potassium, and sodium oxybates). 22 April 2021
Biotechnology
US RNAi therapeutics company Alnylam Pharmaceuticals has announced full positive results from the HELIOS-A Phase III study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis, which met its primary and both secondary endpoints at nine months in patients with hereditary ATTR (hATTR) amyloidosis with polyneuropathy. 20 April 2021
Biotechnology
US biotech major Biogen today announced new data from the Spinraza (nusinersen) clinical development program aimed at optimizing outcomes for people with spinal muscular atrophy (SMA) and advancing understanding of the disease. 19 April 2021
Biotechnology
Swiss pharma giant Novartis has announced new post hoc data from the Phase III ASCLEPIOS trials of Kesimpta (ofatumumab). 16 April 2021
Biotechnology
Roche today announced new Ocrevus (ocrelizumab) analyses supporting its significant benefit on disease progression in early-stage relapsing-remitting multiple sclerosis (RRMS) and primary progressive MS (PPMS) as well as demonstrating high persistence and strong adherence to twice-yearly (six-monthly) dosing. 16 April 2021
Biotechnology
PTC Therapeutics has announced new data showing continued improvements in motor milestones in infants with type 1 spinal muscular atrophy (SMA) after two years of treatment with Evrysdi (risdiplam). 15 April 2021
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze